1
|
Pedersen PS, Blakemore DC, Chinigo GM, Knauber T, MacMillan DWC. One-Pot Synthesis of Sulfonamides from Unactivated Acids and Amines via Aromatic Decarboxylative Halosulfonylation. J Am Chem Soc 2023; 145:21189-21196. [PMID: 37729614 PMCID: PMC10680120 DOI: 10.1021/jacs.3c08218] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/22/2023]
Abstract
The coupling of carboxylic acids and amines to form amide linkages is the most commonly performed reaction in the pharmaceutical industry. Herein, we report a new strategy that merges these traditional amide coupling partners to generate sulfonamides, important amide bioisosteres. This method leverages copper ligand-to-metal charge transfer (LMCT) to convert aromatic acids to sulfonyl chlorides, followed by one-pot amination to form the corresponding sulfonamide. This process requires no prefunctionalization of the native acid or amine and extends to a diverse set of aryl, heteroaryl, and s-rich aliphatic substrates. Further, we extend this strategy to the synthesis of (hetero)aryl sulfonyl fluorides, which have found utility as "click" handles in chemical probes and programmable bifunctional reagents. Finally, we demonstrate the utility of these protocols in pharmaceutical analogue synthesis.
Collapse
Affiliation(s)
- P Scott Pedersen
- Merck Center for Catalysis, Princeton University, Princeton, New Jersey 08544, United States
| | - David C Blakemore
- Worldwide Research and Development, Pfizer, Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Gary M Chinigo
- Worldwide Research and Development, Pfizer, Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Thomas Knauber
- Worldwide Research and Development, Pfizer, Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - David W C MacMillan
- Merck Center for Catalysis, Princeton University, Princeton, New Jersey 08544, United States
| |
Collapse
|
2
|
Li X, Guo T, Feng Q, Bai T, Wu L, Liu Y, Zheng X, Jia J, Pei J, Wu S, Song Y, Zhang Y. Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs. Eur J Med Chem 2022; 228:114035. [PMID: 34902735 DOI: 10.1016/j.ejmech.2021.114035] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2021] [Revised: 11/11/2021] [Accepted: 11/30/2021] [Indexed: 01/07/2023]
Abstract
Many populations suffer from thrombotic disorders such as stroke, myocardial infarction, unstable angina and thromboembolic disease. Thrombus is one of the major threatening factors to human health and the prevalence of cardio-cerebrovascular diseases induced by thrombus is growing worldwide, even some persons got rare and severe blood clots after receiving the AstraZeneca COVID vaccine unexpectedly. In terms of mechanism of thrombosis, antithrombotic drugs have been divided into three categories including anticoagulants, platelet inhibitors and fibrinolytics. Nowadays, a large number of new compounds possessing antithrombotic activities are emerging in an effort to remove the inevitable drawbacks of previously approved drugs such as the high risk of bleeding, a slow onset of action and a narrow therapeutic window. In this review, we describe the causes and mechanisms of thrombus formation firstly, and then summarize these reported active compounds as potential antithrombotic candidates based on their respective mechanism, hoping to promote the development of more effective bioactive molecules for treating thrombotic disorders.
Collapse
Affiliation(s)
- Xiaoan Li
- Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Biomedicine Key Laboratory of Shaanxi Province, Northwest University, Xi'an, 710069, China; Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China
| | - Tiantian Guo
- College of Food Science and Technology, Northwest University, Xi'an, 710069, China
| | - Qian Feng
- Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Biomedicine Key Laboratory of Shaanxi Province, Northwest University, Xi'an, 710069, China
| | - Tiantian Bai
- Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Biomedicine Key Laboratory of Shaanxi Province, Northwest University, Xi'an, 710069, China
| | - Lei Wu
- Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Biomedicine Key Laboratory of Shaanxi Province, Northwest University, Xi'an, 710069, China
| | - Yubo Liu
- Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Biomedicine Key Laboratory of Shaanxi Province, Northwest University, Xi'an, 710069, China
| | - Xu Zheng
- Shaanxi Institute for Food and Drug, Xi'an, 710000, China
| | - Jianzhong Jia
- Shaanxi Institute for Food and Drug, Xi'an, 710000, China
| | - Jin Pei
- Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China
| | - Shaoping Wu
- Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Biomedicine Key Laboratory of Shaanxi Province, Northwest University, Xi'an, 710069, China.
| | - Yiming Song
- School of Chemical Engineering, Northwest University, 229 Taibai Road, Xi'an, Shaanxi, 710069, China.
| | - Yongmin Zhang
- Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Biomedicine Key Laboratory of Shaanxi Province, Northwest University, Xi'an, 710069, China; Sorbonne Université, CNRS, Institut Parisien de Chimie Moléculaire, UMR 8232, 4 Place Jussieu, 75005, Paris, France
| |
Collapse
|
3
|
Jun JJ, Duscharla D, Ummanni R, Hanson PR, Malhotra SV. Investigation on the Anticancer Activity of Symmetric and Unsymmetric Cyclic Sulfamides. ACS Med Chem Lett 2021; 12:202-210. [PMID: 33603966 DOI: 10.1021/acsmedchemlett.0c00460] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Accepted: 01/08/2021] [Indexed: 12/20/2022] Open
Abstract
The sulfamide functional group has been extensively employed in organic synthesis to discover probes and drugs in various applications such as cancer, human immunodeficiency virus (HIV), virus, and diabetes. Herein, we describe the synthesis of 7-membered symmetric and unsymmetric sulfamide compounds and their biological evaluation through the National Cancer Institute (NCI) panel of 60 human tumor cell lines (NCI-60) and the mechanism of action study. The results of a study from the NCI-60 cell line exhibited that many synthesized cyclic sulfamide compounds inhibited breast cancer (MDA-MB-468). The mechanism of action study of a representative compound 18 showed the inhibition of proliferation and apoptosis in A549 lung cancer cells.
Collapse
Affiliation(s)
- Jaden Jungho Jun
- Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, National Institutes of Health (NIH) National Center of Excellence for Computational Drug Abuse Research, Drug Discovery Institute, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States
- Department of Chemistry, University of Kansas, 1567 Irving Hill Road, Lawrence, Kansas 66045-7582, United States
| | - Divya Duscharla
- Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India
| | - Ramesh Ummanni
- Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India
| | - Paul R. Hanson
- Department of Chemistry, University of Kansas, 1567 Irving Hill Road, Lawrence, Kansas 66045-7582, United States
| | - Sanjay V. Malhotra
- Department of Cell, Development and Cancer Biology, Oregon Health & Science University, Portland, Oregon 97201, United States
- Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon 97201, United States
| |
Collapse
|
4
|
Ishihara T, Mori K, Munakata R, Moritomo A. A Novel Fragment Recommendation Workflow using Direct and Indirect Transfer of SAR According to Integrated Similarities of Scaffold Motifs and SAR Trends: Application to Identifying Factor Xa Inhibitors. CHEM-BIO INFORMATICS JOURNAL 2017. [DOI: 10.1273/cbij.17.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Tsukasa Ishihara
- Medicinal Chemistry Research Labs., Drug Discovery Research, Astellas Pharma Inc
| | - Kenichi Mori
- Medicinal Chemistry Research Labs., Drug Discovery Research, Astellas Pharma Inc
| | - Ryosuke Munakata
- Medicinal Chemistry Research Labs., Drug Discovery Research, Astellas Pharma Inc
| | - Ayako Moritomo
- Medicinal Chemistry Research Labs., Drug Discovery Research, Astellas Pharma Inc
| |
Collapse
|
5
|
de Candia M, Lopopolo G, Altomare C. Novel factor Xa inhibitors: a patent review. Expert Opin Ther Pat 2010; 19:1535-80. [PMID: 19743898 DOI: 10.1517/13543770903270532] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
IMPORTANCE OF THE FIELD New oral anticoagulants with favorable safety profiles and fixed doses are required for the management of thromboembolism and stroke prevention in patients with atrial fibrillation. Among them, fXa inhibitors (the so-called xabans) are attractive options that can overcome limitations (e.g., bleeding) of the current oral antithrombotic therapy. The rational design of small-molecule direct fXa inhibitors, whose importance is testified by the growing number of publications and patents recently registered, has been fully supported by the X-ray crystallography of enzyme-ligand complexes. AREAS COVERED IN THIS REVIEW Pubmed, SciFinder Scholar, ISI web of knowledge(SM), http://ep.espacenet.com/ and Google websites were used as the main sources for literature retrieving, and > 100 patents filed between 2006 and April 2009, reviewed and discussed herein, highlight the variety among the P1 and P4 moieties on suitable scaffolds. WHAT THE READER WILL GAIN The replacement of the benzamidine P1 moiety, which characterizes the first generation, with less basic bioisosteric or nonpolar neutral P1 groups led to the disclosure of numerous fXa inhibitors with high potency, selectivity and oral bioavailability. Novel selective fXa inhibitors with stable pharmacokinetics, better therapeutic windows and ease-of-use than the existing anticoagulants are currently under advanced stage clinical trials. TAKE-HOME MESSAGE Available data from Phase II and Phase III studies reflect the drive towards fXa inhibitors as potentially more effective and safer antithrombotic drugs. Their development is expected to address two major needs for anticoagulation, namely safety and ease-of-use, and to significantly affect the anticoagulant market.
Collapse
Affiliation(s)
- Modesto de Candia
- University of Bari, Dipartimento Farmaco-Chimico, Via E. Orabona 4, I-70125 Bari, Italy
| | | | | |
Collapse
|
6
|
Imaeda Y, Miyawaki T, Sakamoto H, Itoh F, Konishi N, Hiroe K, Kawamura M, Tanaka T, Kubo K. Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors. Bioorg Med Chem 2008; 16:2243-60. [DOI: 10.1016/j.bmc.2007.11.073] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2007] [Revised: 11/22/2007] [Accepted: 11/27/2007] [Indexed: 10/22/2022]
|
7
|
Noguchi T, Tanaka N, Nishimata T, Goto R, Hayakawa M, Sugidachi A, Ogawa T, Asai F, Fujimoto K. Cinnamyl Derivatives: Synthesis and Factor Xa (FXa) Inhibitory Activities. Chem Pharm Bull (Tokyo) 2008; 56:758-70. [DOI: 10.1248/cpb.56.758] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Tetsuji Noguchi
- Medicinal Chemistry Research Laboratories II, Daiichi Sankyo Co., Ltd
| | - Naoki Tanaka
- Medicinal Chemistry Research Laboratories I, Daiichi Sankyo Co., Ltd
| | - Toyoki Nishimata
- Medicinal Chemistry Research Laboratories I, Daiichi Sankyo Co., Ltd
| | - Riki Goto
- Medicinal Chemistry Research Laboratories I, Daiichi Sankyo Co., Ltd
| | - Miho Hayakawa
- Medicinal Chemistry Research Laboratories II, Daiichi Sankyo Co., Ltd
| | | | | | - Fumitoshi Asai
- Biological Research Laboratories II, Daiichi Sankyo Co., Ltd
| | - Koichi Fujimoto
- Medicinal Chemistry Research Laboratories I, Daiichi Sankyo Co., Ltd
| |
Collapse
|
8
|
Casimiro-Garcia A, Dudley DA, Heemstra RJ, Filipski KJ, Bigge CF, Edmunds JJ. Progress in the discovery of Factor Xa inhibitors. Expert Opin Ther Pat 2006. [DOI: 10.1517/13543776.16.2.119] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
9
|
Ueno H, Yokota K, Hoshi JI, Yasue K, Hayashi M, Uchida I, Aisaka K, Hase Y, Katoh S, Cho H. Discovery of novel tetrahydroisoquinoline derivatives as potent and selective factor Xa inhibitors. Bioorg Med Chem Lett 2005; 15:185-9. [PMID: 15582437 DOI: 10.1016/j.bmcl.2004.10.033] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2004] [Accepted: 10/05/2004] [Indexed: 11/20/2022]
Abstract
A series of novel 2,7-disubstituted tetrahydroisoquinoline derivatives were designed and synthesized. Among these derivatives, compounds 1 and 2 (JTV-803) exhibited potent inhibitory activity against FXa and good selectivity with respect to other serine proteases (thrombin, plasmin, and trypsin). In addition, compound 2 exhibited potent anti-FXa activity after intravenous and oral administration to cynomolgus monkey, and showed a dose-dependent antithrombotic effect in a rat model of venous thrombosis.
Collapse
Affiliation(s)
- Hiroshi Ueno
- Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Koshio H, Ishihara T, Yamada H, Hirayama F, Matsumoto Y, Yanagisawa I. An Easy Access to 7-Methyl-2-naphthalenecarbonitrile. Chem Pharm Bull (Tokyo) 2005; 53:448-50. [PMID: 15802851 DOI: 10.1248/cpb.53.448] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A practical and cost-effective procedure has been developed for the synthesis of 7-methyl-2-naphthalenecarbonitrile, the precursor of the anticoagulant agents YM-60828 or YM-96765. This new route generates the key intermediate in only two steps from readily available 3-cyanopropionaldehyde dimethyl acetal and m-tolualdehyde, without requiring chromatographic purification. The synthesis involves condensation of the cyano derivative with the aldehyde and subsequent cyclodehydration.
Collapse
Affiliation(s)
- Hiroyuki Koshio
- Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co. Ltd., Ibaraki.
| | | | | | | | | | | |
Collapse
|
11
|
Gu YG, Florjancic AS, Clark RF, Zhang T, Cooper CS, Anderson DD, Lerner CG, McCall JO, Cai Y, Black-Schaefer CL, Stamper GF, Hajduk PJ, Beutel BA. Structure-activity relationships of novel potent MurF inhibitors. Bioorg Med Chem Lett 2004; 14:267-70. [PMID: 14684340 DOI: 10.1016/j.bmcl.2003.09.073] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
A novel class of MurF inhibitors was discovered and structure-activity relationship studies have led to several potent compounds with IC(50)=22 approximately 70 nM. Unfortunately, none of these potent MurF inhibitors exhibited significant antibacterial activity even in the presence of bacterial cell permeabilizers.
Collapse
Affiliation(s)
- Yu Gui Gu
- Infectious Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 200 Abbott Park Road, Abbott Park, IL 60064, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Ueno H, Katoh S, Yokota K, Hoshi JI, Hayashi M, Uchida I, Aisaka K, Hase Y, Cho H. Structure–activity relationships of potent and selective factor Xa inhibitors: benzimidazole derivatives with the side chain oriented to the prime site of factor Xa. Bioorg Med Chem Lett 2004; 14:4281-6. [PMID: 15261287 DOI: 10.1016/j.bmcl.2004.05.092] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2004] [Accepted: 05/31/2004] [Indexed: 11/19/2022]
Abstract
A series of benzimidazole derivatives with the side chain on the nitrogen atom oriented to the prime site of factor Xa (FXa) were designed and synthesized. Compounds with substituted aminocarbonylmethyl groups as the side chain showed potent FXa inhibitory activity. Compounds 1 and 2 exhibited most potent inhibitory activity and were effective as anticoagulants in a DIC model.
Collapse
Affiliation(s)
- Hiroshi Ueno
- Central Pharmaceutical Research Institute, Japan Tobacco Inc, 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Koshio H, Hirayama F, Ishihara T, Taniuchi Y, Sato K, Sakai-Moritani Y, Kaku S, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto SI. Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity. Bioorg Med Chem 2004; 12:2179-91. [PMID: 15080918 DOI: 10.1016/j.bmc.2004.02.022] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2003] [Revised: 02/19/2004] [Accepted: 02/19/2004] [Indexed: 10/26/2022]
Abstract
Factor Xa (fXa) is a serine protease involved in the coagulation cascade, which has received great interest as a potential target for the development of new antithrombotic drugs. Herein we report a novel series of fXa inhibitors in which the 1,4-diazepane moiety was designed to interact with the S4 aryl-binding domain of the fXa active site. Compound 13 (YM-96765) showed potent fXa inhibitory activity (IC(50) = 6.8 nM) and effective antithrombotic activity without prolonging bleeding time.
Collapse
Affiliation(s)
- Hiroyuki Koshio
- Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd, 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Kontogiorgis CA, Hadjipavlou-Litina D. Current trends in quantitative structure activity relationships on FXa inhibitors: Evaluation and comparative analysis. Med Res Rev 2004; 24:687-747. [PMID: 15250038 DOI: 10.1002/med.20006] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
This article evaluates the quantitative structure activity relationships of FXa inhibitors, using the C-QSAR program of Biobyte. Diaryloxypyridines, aminophenols, biaryl isoxazoline derivatives, 1,2-dibenzamidobenzenes, 3-amidinophenylalanine derivatives, benzoxazinones, naphthoanilides, tetrazoles, glucolic and mandelic acid derivatives were included in this survey. Clog P plays a significant role in the QSAR, especially as hydrophilicity. In the most of the cases, CMR/MR molar refractivity as well as sterimol parameters (B5 and L) are important. Electronic effects with the exception of the Hammett's constant sigmam, are not found to govern the biological activity. Es was found to be important indicator variables were used after the best model was found to account for the usual structural features.
Collapse
Affiliation(s)
- Christos A Kontogiorgis
- Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
| | | |
Collapse
|
15
|
Dahl JE, Liu SG, Carlson RMK. Isolation and structure of higher diamondoids, nanometer-sized diamond molecules. Science 2003; 299:96-9. [PMID: 12459548 DOI: 10.1126/science.1078239] [Citation(s) in RCA: 497] [Impact Index Per Article: 23.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
We exploited the exceptional thermal stability and diverse molecular shapes of higher diamondoids (C22 and higher polymantanes) to isolate them from petroleum. Molecules containing 4 to 11 diamond-crystal cages were isolated and crystallized, and we obtained single-crystal x-ray structures for representatives from three families. Rigidity, strength, remarkable assortments of three- dimensional shapes, including resolvable chiral forms, and multiple, readily derivatizable attachment sites make them valuable nanometer-size molecular building blocks.
Collapse
Affiliation(s)
- J E Dahl
- MolecularDiamond Technologies, ChevronTexaco Technology Ventures, Post Office Box 1627, Richmond, CA 94802, USA
| | | | | |
Collapse
|